• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Longeveron Inc.

    2/14/24 3:41:44 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    SC 13G 1 armistice-lgvn123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Longeveron Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    54303L104

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  54303L104
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,836,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,836,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,836,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.31%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  54303L104
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,836,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,836,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,836,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.31%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 54303L104
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Longeveron Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1951 NW 7th Avenue, Suite 520

    Miami, Florida 33136

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock (“Shares”)

     

    Item 2.(e) CUSIP No.:

    54303L104

     

    CUSIP No.  54303L104
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 54303L104
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of December 31, 2023:

    Armistice Capital, LLC - 1,836,000

    Steven Boyd - 1,836,000  

    (b) Percent of Class as of December 31, 2023:

    Armistice Capital, LLC - 7.31%

    Steven Boyd - 7.31% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 1,836,000

    Steven Boyd - 1,836,000 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 1,836,000

    Steven Boyd - 1,836,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 54303L104
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 54303L104
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $LGVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Longeveron® to Attend BIO International Convention 2025

      Focus on potential partnership and strategic opportunities for the Company's stem cell therapy program for Alzheimer's diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer's disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in the peer reviewed jour

      5/20/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

      Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. "We're proud to be a Semifinalist team of X

      5/12/25 7:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

      MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

      11/11/24 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neha Motwani Elected to Longeveron® Board of Directors

      MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte

      7/9/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

      MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the

      7/8/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Financials

    Live finance-specific insights

    See more
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

      5/2/25 8:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

      2/28/25 4:04:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Soffer Rock sold $2,640 worth of shares (2,000 units at $1.32), decreasing direct ownership by 0.86% to 230,034 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/27/25 6:52:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Hare Joshua sold $7,367 worth of shares (5,250 units at $1.40), decreasing direct ownership by 0.72% to 721,796 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/16/25 6:00:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Blass Devin claimed ownership of 121,084 shares (SEC Form 3)

      3 - Longeveron Inc. (0001721484) (Issuer)

      4/21/25 8:05:05 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:29 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hashad Mohamed Wa'El Ahmed bought $24,999 worth of shares (10,638 units at $2.35), increasing direct ownership by 118% to 19,616 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soffer Rock bought $325,000 worth of shares (138,298 units at $2.35), increasing direct ownership by 197% to 208,534 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    SEC Filings

    See more
    • SEC Form 144 filed by Longeveron Inc.

      144 - Longeveron Inc. (0001721484) (Subject)

      5/15/25 3:20:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:11:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Longeveron Inc.

      10-Q - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:00:27 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

      SC 13G/A - Longeveron Inc. (0001721484) (Subject)

      11/14/24 4:20:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      7/26/24 4:18:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      4/17/24 4:03:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Longeveron with a new price target

      ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

      12/6/24 7:54:21 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EF Hutton initiated coverage on Longeveron with a new price target

      EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

      1/5/22 10:22:40 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care